- Home
- CHMI vs TCRX Comparison
CHMI vs TCRX Comparison
Compare CHMI & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHMI
- TCRX
- Stock Information
- Founded
- CHMI 2012
- TCRX 2018
- Country
- CHMI United States
- TCRX United States
- Employees
- CHMI N/A
- TCRX N/A
- Industry
- CHMI Real Estate Investment Trusts
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- CHMI Real Estate
- TCRX Health Care
- Exchange
- CHMI Nasdaq
- TCRX Nasdaq
- Market Cap
- CHMI 92.0M
- TCRX 98.5M
- IPO Year
- CHMI 2013
- TCRX 2021
- Fundamental
- Price
- CHMI $3.30
- TCRX $1.38
- Analyst Decision
- CHMI Buy
- TCRX Strong Buy
- Analyst Count
- CHMI 3
- TCRX 6
- Target Price
- CHMI $5.00
- TCRX $9.83
- AVG Volume (30 Days)
- CHMI 344.9K
- TCRX 442.7K
- Earning Date
- CHMI 03-06-2025
- TCRX 03-05-2025
- Dividend Yield
- CHMI 18.21%
- TCRX N/A
- EPS Growth
- CHMI N/A
- TCRX N/A
- EPS
- CHMI 0.07
- TCRX N/A
- Revenue
- CHMI $46,993,000.00
- TCRX $2,816,000.00
- Revenue This Year
- CHMI $14.91
- TCRX $32.21
- Revenue Next Year
- CHMI N/A
- TCRX $118.35
- P/E Ratio
- CHMI $48.24
- TCRX N/A
- Revenue Growth
- CHMI N/A
- TCRX N/A
- 52 Week Low
- CHMI $2.50
- TCRX $1.28
- 52 Week High
- CHMI $3.99
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- CHMI 36.67
- TCRX 31.10
- Support Level
- CHMI $3.54
- TCRX $1.44
- Resistance Level
- CHMI $3.67
- TCRX $1.76
- Average True Range (ATR)
- CHMI 0.10
- TCRX 0.17
- MACD
- CHMI -0.03
- TCRX -0.01
- Stochastic Oscillator
- CHMI 10.59
- TCRX 16.39
About CHMI Cherry Hill Mortgage Investment Corporation
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.